Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 2.15

(12.57%)

Revenue Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual revenue in 2023 was 1.35 Million SEK , up 98.59% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly revenue in 2024 Q2 was 724 Thousand SEK , down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported a annual revenue of 682.79 Thousand SEK in annual revenue 2022, up 6727.3% from previous year.
Prostatype Genomics AB (publ) reported a annual revenue of 10 Thousand SEK in annual revenue 2021, down -98.54% from previous year.
Prostatype Genomics AB (publ) reported a quarterly revenue of 724 Thousand SEK for 2024 Q1, down -55.86% from previous quarter.
Prostatype Genomics AB (publ) reported a quarterly revenue of 391.68 Thousand SEK for 2023 Q1, up 28.71% from previous quarter.

Annual Revenue Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Revenue of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Revenue	Revenue Growth
2023	1.35 Million SEK	98.59%
2022	682.79 Thousand SEK	6727.3%
2021	10 Thousand SEK	-98.54%
2020	683.87 Thousand SEK	0.0%
2018	74.08 Thousand SEK	-54.22%
2017	161.84 Thousand SEK	-96.76%
2016	4.99 Million SEK	4821.69%
2015	101.5 Thousand SEK	0.0%

Year	Revenue	Revenue Growth
2024 Q2	724 Thousand SEK	0.0%
2024 Q1	724 Thousand SEK	-55.86%
2023 Q1	391.68 Thousand SEK	28.71%
2023 FY	1.35 Million SEK	98.59%
2023 Q2	55.68 Thousand SEK	-85.78%
2023 Q3	1.64 Million SEK	2845.86%
2023 Q4	1.64 Million SEK	0.0%
2022 FY	682.79 Thousand SEK	6727.3%
2022 Q4	304.32 Thousand SEK	177.27%
2022 Q3	109.75 Thousand SEK	1278.83%
2022 Q2	7960.00 SEK	-96.95%
2022 Q1	260.76 Thousand SEK	26075900.0%
2021 Q1	4998.00 SEK	-99.55%
2021 FY	10 Thousand SEK	-98.54%
2021 Q4	1.00 SEK	-100.0%
2021 Q3	426.44 Thousand SEK	8425.43%
2021 Q2	5002.00 SEK	0.08%
2020 FY	683.87 Thousand SEK	0.0%
2020 Q4	1.1 Million SEK	7251.19%
2020 Q3	15 Thousand SEK	-97.5%
2020 Q2	601.05 Thousand SEK	4795.34%
2020 Q1	12.27 Thousand SEK	-98.54%
2019 Q4	838.14 Thousand SEK	179.39%
2019 Q3	299.99 Thousand SEK	0.0%
2018 FY	74.08 Thousand SEK	-54.22%
2017 FY	161.84 Thousand SEK	-96.76%
2016 FY	4.99 Million SEK	4821.69%
2015 FY	101.5 Thousand SEK	0.0%

Peer Revenue Comparison of Prostatype Genomics AB (publ)

Name	Revenue	Revenue Difference
AroCell AB (publ)	43.03 Million SEK	96.849%
Devyser Diagnostics AB (publ)	169.3 Million SEK	99.199%
Immunovia AB (publ)	1.57 Million SEK	13.905%
SenzaGen AB	49.87 Million SEK	97.281%
Spermosens AB	- SEK	-Infinity%